Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors

Katja Freundt, Thekla Meyners, Amira Bajrovic, Hiba Basic, Johann H. Karstens, Irenaeus A. Adamietz, Volker Rudat, Steven E. Schild, Juergen Dunst, Dirk Rades

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Radiotherapy alone is the most common treatment for metastatic spinal cord compression (MSCC). Patients with relatively radioresistant tumors and oligometastatic disease may benefit from more intensive therapies (surgery, high-precision radiotherapy). If such therapies are not available, one can speculate whether patients benefit from dose escalation beyond the standard regimen 30 Gy in ten fractions. Patientsand Methods: Of 206 patients with MSCC from relatively radioresistant tumors (renal cell carcinoma, colorectal cancer, malignant melanoma), 51 had oligometastatic disease (no visceral or other bone metastases, involvement of only one to three vertebrae). In this subset, 21 patients receiving 30 Gy in ten fractions were retrospectively compared to 30 patients receiving higher doses. Seven further potential prognostic factors were investigated: age, gender, tumor type, performance status, interval from tumor diagnosis to radiotherapy of MSCC, pretreatment ambulatory status, and time developing motor deficits before radiotherapy. Results: Motor function improved in 52% of patients after 30 Gy and 40% after higher doses (p - 0.44). On multivariate analysis, functional outcome was associated with interval from tumor diagnosis to radiotherapy (p - 0.020). 1-year local control rates were 84% after 30 Gy and 82% after higher doses (p - 0.75). No factor was associated with local control. 1-year survival rates were 76% after 30 Gy and 63% after higher doses (p - 0.52). On multivariate analysis, survival was associated with performance status (p - 0.022) and interval from tumor diagnosis to radiotherapy (p - 0.039), and almost with pretreatment ambulatory status (p-0.069). Conclusion: Dose escalation beyond 30 Gy in ten fractions did not improve motor function, local control, and survival in MSCC patients with oligometastatic disease from relatively radioresistant tumors.

Original languageEnglish (US)
Pages (from-to)218-223
Number of pages6
JournalStrahlentherapie und Onkologie
Volume186
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Spinal Cord Compression
Radiotherapy
Neoplasms
Multivariate Analysis
Survival
Renal Cell Carcinoma
Colorectal Neoplasms
Melanoma
Spine
Therapeutics
Survival Rate
Neoplasm Metastasis
Bone and Bones

Keywords

  • Dose escalation
  • Metastatic spinal cord compression
  • Oligometastatic disease
  • Relatively radioresistant tumors
  • Treatment outcome

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology
  • Medicine(all)

Cite this

Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. / Freundt, Katja; Meyners, Thekla; Bajrovic, Amira; Basic, Hiba; Karstens, Johann H.; Adamietz, Irenaeus A.; Rudat, Volker; Schild, Steven E.; Dunst, Juergen; Rades, Dirk.

In: Strahlentherapie und Onkologie, Vol. 186, No. 4, 04.2010, p. 218-223.

Research output: Contribution to journalArticle

Freundt, K, Meyners, T, Bajrovic, A, Basic, H, Karstens, JH, Adamietz, IA, Rudat, V, Schild, SE, Dunst, J & Rades, D 2010, 'Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors', Strahlentherapie und Onkologie, vol. 186, no. 4, pp. 218-223. https://doi.org/10.1007/s00066-010-2110-9
Freundt, Katja ; Meyners, Thekla ; Bajrovic, Amira ; Basic, Hiba ; Karstens, Johann H. ; Adamietz, Irenaeus A. ; Rudat, Volker ; Schild, Steven E. ; Dunst, Juergen ; Rades, Dirk. / Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. In: Strahlentherapie und Onkologie. 2010 ; Vol. 186, No. 4. pp. 218-223.
@article{aacc1374bb5d4dcf849b896f58bcfd22,
title = "Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors",
abstract = "Background: Radiotherapy alone is the most common treatment for metastatic spinal cord compression (MSCC). Patients with relatively radioresistant tumors and oligometastatic disease may benefit from more intensive therapies (surgery, high-precision radiotherapy). If such therapies are not available, one can speculate whether patients benefit from dose escalation beyond the standard regimen 30 Gy in ten fractions. Patientsand Methods: Of 206 patients with MSCC from relatively radioresistant tumors (renal cell carcinoma, colorectal cancer, malignant melanoma), 51 had oligometastatic disease (no visceral or other bone metastases, involvement of only one to three vertebrae). In this subset, 21 patients receiving 30 Gy in ten fractions were retrospectively compared to 30 patients receiving higher doses. Seven further potential prognostic factors were investigated: age, gender, tumor type, performance status, interval from tumor diagnosis to radiotherapy of MSCC, pretreatment ambulatory status, and time developing motor deficits before radiotherapy. Results: Motor function improved in 52{\%} of patients after 30 Gy and 40{\%} after higher doses (p - 0.44). On multivariate analysis, functional outcome was associated with interval from tumor diagnosis to radiotherapy (p - 0.020). 1-year local control rates were 84{\%} after 30 Gy and 82{\%} after higher doses (p - 0.75). No factor was associated with local control. 1-year survival rates were 76{\%} after 30 Gy and 63{\%} after higher doses (p - 0.52). On multivariate analysis, survival was associated with performance status (p - 0.022) and interval from tumor diagnosis to radiotherapy (p - 0.039), and almost with pretreatment ambulatory status (p-0.069). Conclusion: Dose escalation beyond 30 Gy in ten fractions did not improve motor function, local control, and survival in MSCC patients with oligometastatic disease from relatively radioresistant tumors.",
keywords = "Dose escalation, Metastatic spinal cord compression, Oligometastatic disease, Relatively radioresistant tumors, Treatment outcome",
author = "Katja Freundt and Thekla Meyners and Amira Bajrovic and Hiba Basic and Karstens, {Johann H.} and Adamietz, {Irenaeus A.} and Volker Rudat and Schild, {Steven E.} and Juergen Dunst and Dirk Rades",
year = "2010",
month = "4",
doi = "10.1007/s00066-010-2110-9",
language = "English (US)",
volume = "186",
pages = "218--223",
journal = "Strahlentherapie und Onkologie : Organ der Deutschen R{\"o}ntgengesellschaft ... [et al]",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "4",

}

TY - JOUR

T1 - Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors

AU - Freundt, Katja

AU - Meyners, Thekla

AU - Bajrovic, Amira

AU - Basic, Hiba

AU - Karstens, Johann H.

AU - Adamietz, Irenaeus A.

AU - Rudat, Volker

AU - Schild, Steven E.

AU - Dunst, Juergen

AU - Rades, Dirk

PY - 2010/4

Y1 - 2010/4

N2 - Background: Radiotherapy alone is the most common treatment for metastatic spinal cord compression (MSCC). Patients with relatively radioresistant tumors and oligometastatic disease may benefit from more intensive therapies (surgery, high-precision radiotherapy). If such therapies are not available, one can speculate whether patients benefit from dose escalation beyond the standard regimen 30 Gy in ten fractions. Patientsand Methods: Of 206 patients with MSCC from relatively radioresistant tumors (renal cell carcinoma, colorectal cancer, malignant melanoma), 51 had oligometastatic disease (no visceral or other bone metastases, involvement of only one to three vertebrae). In this subset, 21 patients receiving 30 Gy in ten fractions were retrospectively compared to 30 patients receiving higher doses. Seven further potential prognostic factors were investigated: age, gender, tumor type, performance status, interval from tumor diagnosis to radiotherapy of MSCC, pretreatment ambulatory status, and time developing motor deficits before radiotherapy. Results: Motor function improved in 52% of patients after 30 Gy and 40% after higher doses (p - 0.44). On multivariate analysis, functional outcome was associated with interval from tumor diagnosis to radiotherapy (p - 0.020). 1-year local control rates were 84% after 30 Gy and 82% after higher doses (p - 0.75). No factor was associated with local control. 1-year survival rates were 76% after 30 Gy and 63% after higher doses (p - 0.52). On multivariate analysis, survival was associated with performance status (p - 0.022) and interval from tumor diagnosis to radiotherapy (p - 0.039), and almost with pretreatment ambulatory status (p-0.069). Conclusion: Dose escalation beyond 30 Gy in ten fractions did not improve motor function, local control, and survival in MSCC patients with oligometastatic disease from relatively radioresistant tumors.

AB - Background: Radiotherapy alone is the most common treatment for metastatic spinal cord compression (MSCC). Patients with relatively radioresistant tumors and oligometastatic disease may benefit from more intensive therapies (surgery, high-precision radiotherapy). If such therapies are not available, one can speculate whether patients benefit from dose escalation beyond the standard regimen 30 Gy in ten fractions. Patientsand Methods: Of 206 patients with MSCC from relatively radioresistant tumors (renal cell carcinoma, colorectal cancer, malignant melanoma), 51 had oligometastatic disease (no visceral or other bone metastases, involvement of only one to three vertebrae). In this subset, 21 patients receiving 30 Gy in ten fractions were retrospectively compared to 30 patients receiving higher doses. Seven further potential prognostic factors were investigated: age, gender, tumor type, performance status, interval from tumor diagnosis to radiotherapy of MSCC, pretreatment ambulatory status, and time developing motor deficits before radiotherapy. Results: Motor function improved in 52% of patients after 30 Gy and 40% after higher doses (p - 0.44). On multivariate analysis, functional outcome was associated with interval from tumor diagnosis to radiotherapy (p - 0.020). 1-year local control rates were 84% after 30 Gy and 82% after higher doses (p - 0.75). No factor was associated with local control. 1-year survival rates were 76% after 30 Gy and 63% after higher doses (p - 0.52). On multivariate analysis, survival was associated with performance status (p - 0.022) and interval from tumor diagnosis to radiotherapy (p - 0.039), and almost with pretreatment ambulatory status (p-0.069). Conclusion: Dose escalation beyond 30 Gy in ten fractions did not improve motor function, local control, and survival in MSCC patients with oligometastatic disease from relatively radioresistant tumors.

KW - Dose escalation

KW - Metastatic spinal cord compression

KW - Oligometastatic disease

KW - Relatively radioresistant tumors

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=77951638741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951638741&partnerID=8YFLogxK

U2 - 10.1007/s00066-010-2110-9

DO - 10.1007/s00066-010-2110-9

M3 - Article

C2 - 20354660

AN - SCOPUS:77951638741

VL - 186

SP - 218

EP - 223

JO - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

JF - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

SN - 0179-7158

IS - 4

ER -